Search

Your search keyword '"Argueta, Kimberly"' showing total 83 results

Search Constraints

Start Over You searched for: Author "Argueta, Kimberly" Remove constraint Author: "Argueta, Kimberly"
83 results on '"Argueta, Kimberly"'

Search Results

1. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

2. Proteomic characterization of acute kidney injury in patients hospitalized with SARS-CoV2 infection

3. Circulating proteins to predict COVID-19 severity

4. A methylation clock model of mild SARS‐CoV‐2 infection provides insight into immune dysregulation

5. Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

6. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

7. Supplementary Table 6 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

8. Supplementary Figure 6 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

9. Supplementary Figure 8 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

10. Supplementary Table 3 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

11. Supplementary Figure 1 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

12. Supplementary Table 1 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

13. Supplementary Figure 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

14. Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

15. Supplementary Figure 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

16. Supplementary Table 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

17. Supplementary Table 4 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

18. Supplementary Figure 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

19. Supplementary Table 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

20. Supplementary Figure 3 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

21. Supplementary Figure 4 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

22. Supplementary Table 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

23. Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children

24. Proteomic Characterization of Acute Kidney Injury in Patients Hospitalized with SARS-CoV2 Infection

25. 1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma

26. Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer

27. Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.

28. Additional file 3 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

29. Additional file 6 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

30. Additional file 1 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

31. Additional file 2 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

32. Additional file 5 of The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

33. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

34. Proteomic Characterization of Acute Kidney Injury in Patients Hospitalized with SARS-CoV2 Infection

35. Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)

36. Climate change is the enemy of mankind

37. How to choose the best way of online learning

38. The spread of COVID-19 in Houston should be addressed

40. Sampling the host response to SARS-CoV-2 in hospitals under siege

41. The benefits of volunteering go beyond helping your community

42. Don't forget to reach out to your loved ones, socialize

43. Decreasing your screen time might be the best thing for your health

44. Voter education is more important than ever before

45. Universities should lower tuition in light of the pandemic

46. We're all in the same boat: there is no shame in seeking counseling

47. Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

48. Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege

49. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

50. Proteomic Characterization of Acute Kidney Injury in Patients Hospitalized with SARS-CoV2 Infection.

Catalog

Books, media, physical & digital resources